|
125 Companies |
|
183 Products |
|
183 Products |
|
133 Mechanisms of Action |
|
1 Trial |
|
2306 News |
|
| «12...2021222324252627282930...4041» |
- Tysabri (natalizumab) / Biogen, Royalty, Betaseron (IFN-?-1b) / Bayer
Trial completion: Natalizumab De-escalation With Interferon Beta-1b (clinicaltrials.gov) - Mar 12, 2014
P4, N=19, Completed, Sponsor: Claudio Gobbi
Active, not recruiting --> Completed
- ||||| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Enrollment closed: Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS) (clinicaltrials.gov) - Mar 10, 2014
P3, N=185, Active, not recruiting, Sponsor: Allergan
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Mar 5, 2014
P2, N=104, Completed, Sponsor: Genentech
Recruiting --> Active, not recruiting No longer recruiting --> Completed
- Clinical: Multidimensional Assessment of Fatigue in Multiple Sclerosis- Observational Study - Ticino (clinicaltrials.gov) - Mar 5, 2014
P=N/A, N=100, Recruiting, Sponsor: Claudio Gobbi
- Trial completion, HEOR: EMR 200077-506: A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina (clinicaltrials.gov) - Mar 5, 2014
P=N/A, N=71, Completed, Sponsor: Merck KGaA
No longer recruiting --> Completed Active, not recruiting --> Completed
- | glatiramer acetate / Generic mfg.
Trial completion, Combination therapy: Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx (clinicaltrials.gov) - Mar 5, 2014
P3, N=1008, Completed, Sponsor: Fred Lublin
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Avonex (recombinant IFN-β-1a) / Biogen
New P4 trial, HEOR: SFERA: Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen (clinicaltrials.gov) - Mar 2, 2014
P4, N=50, Recruiting, Sponsor: Biogen Idec
- | ATX-MS-1467 / Apitope
Enrollment open: ATX-MS-1467 in Multiple Sclerosis (clinicaltrials.gov) - Mar 2, 2014
P2, N=20, Recruiting, Sponsor: Merck KGaA
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Enrollment open: BiobankII: Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis (clinicaltrials.gov) - Feb 26, 2014
P4, N=250, Recruiting, Sponsor: Heinrich-Heine University, Duesseldorf
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial initiation date: Exercises for Urinary Incontinence(UI) of Women With Multiple Sclerosis (MS) (clinicaltrials.gov) - Feb 25, 2014
P=N/A, N=34, Not yet recruiting, Sponsor: Hadassah Medical Organization
Not yet recruiting --> Recruiting Initiation date: Jun 2013 --> Feb 2014
- Enrollment change: Exercises for Urinary Incontinence(UI) of Women With Multiple Sclerosis (MS) (clinicaltrials.gov) - Feb 25, 2014
P=N/A, N=34, Not yet recruiting, Sponsor: Hadassah Medical Organization
Initiation date: Jun 2013 --> Feb 2014 N=130 --> 34
- ||| Enrollment change, Metastases: Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease (clinicaltrials.gov) - Feb 24, 2014
P2, N=99, Completed, Sponsor: Children's Oncology Group
N=130 --> 34 N=50 --> 99
- |||| Trial completion, Metastases: Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease (clinicaltrials.gov) - Feb 24, 2014
P2, N=99, Completed, Sponsor: Children's Oncology Group
N=50 --> 99 Active, not recruiting --> Completed
- | Trial completion: Health Behavior Change in Chronic Disease Management (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=20, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | Avonex (recombinant IFN-β-1a) / Biogen
Trial completion, Combination therapy, Monotherapy: AVONEX® Combination Trial - "ACT" (clinicaltrials.gov) - Feb 22, 2014
P4, N=350, Completed, Sponsor: Biogen Idec
Not yet recruiting --> Completed No longer recruiting --> Completed
- |||| Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion: Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Feb 22, 2014
P2, N=270, Completed, Sponsor: PDL BioPharma, Inc.
No longer recruiting --> Completed No longer recruiting --> Completed
- | sodium phenylbutyrate / Generic mfg.
Trial completion: Safety Study of Oral Sodium Phenylbutyrate in Subjects With ALS (Amyotrophic Lateral Sclerosis) (clinicaltrials.gov) - Feb 22, 2014
P1/2, N=40, Completed, Sponsor: Department of Veterans Affairs
No longer recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Herpes Virus-6 and Epilepsy (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=45, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
No longer recruiting --> Completed Recruiting --> Completed
- |||| Omigapil (SNT-317) / Santhera
Trial completion: Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Feb 22, 2014
P2, N=551, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Brain Function in Primary Lateral Sclerosis (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=36, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
No longer recruiting --> Completed Recruiting --> Completed
- | minocycline / Generic mfg.
Trial completion: Minocycline to Treat Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Feb 22, 2014
P3, N=400, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Completed No longer recruiting --> Completed
- | Trial completion: Auditory Function in Patients With and Without Multiple Sclerosis (clinicaltrials.gov) - Feb 22, 2014
P2, N=300, Completed, Sponsor: Department of Veterans Affairs
No longer recruiting --> Completed Recruiting --> Completed
- ||||||| Trial completion: Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial (clinicaltrials.gov) - Feb 22, 2014
P3, N=330, Completed, Sponsor: Mayo Clinic
Recruiting --> Completed No longer recruiting --> Completed
- ||||||| Tysabri (natalizumab) / Biogen, Royalty, Avonex (recombinant IFN-β-1a) / Biogen
Trial completion, Combination therapy: Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis (clinicaltrials.gov) - Feb 22, 2014
P3, N=1200, Completed, Sponsor: Biogen Idec
No longer recruiting --> Completed No longer recruiting --> Completed
- | BHT3009 / Bayhill Therap
Trial completion, IO biomarker: Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis (clinicaltrials.gov) - Feb 22, 2014
P1, N=30, Completed, Sponsor: Bayhill Therapeutics
No longer recruiting --> Completed No longer recruiting --> Completed
- ||||||| Betaseron (IFN-?-1b) / Bayer
Trial completion: BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients (clinicaltrials.gov) - Feb 22, 2014
P3, N=2244, Completed, Sponsor: Bayer
No longer recruiting --> Completed No longer recruiting --> Completed
- | sildenafil / Generic mfg.
Trial completion: The Effect of Sildenafil Citrate (Viagra (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=76, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
No longer recruiting --> Completed Recruiting --> Completed
- |||| Ozespa (briakinumab) / AbbVie
Trial completion: Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS) (clinicaltrials.gov) - Feb 22, 2014
P2, N=215, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Tracleer (bosentan) / J&J, Roche
Trial completion: Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma (clinicaltrials.gov) - Feb 22, 2014
P2/3, N=132, Completed, Sponsor: Actelion
Active, not recruiting --> Completed No longer recruiting --> Completed
- | vinorelbine tartrate / Generic mfg., gemcitabine / Generic mfg.
Trial completion: Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=33, Completed, Sponsor: Children's Oncology Group
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: MR Perfusion Imaging and Hypercapnia (Increased Carbon Dioxide) to Study New Blood Vessel Formation in Multiple Sclerosis (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=50, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed Recruiting --> Completed
- | Trial completion: ERSET: Early Surgical Intervention to Treat Epilepsy (clinicaltrials.gov) - Feb 22, 2014
P3, N=200, Completed, Sponsor: University of California, Los Angeles
Recruiting --> Completed Active, not recruiting --> Completed
- Rebif (human IFN-β-1a) / EMD Serono
Enrollment closed: SOLAR: Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment (clinicaltrials.gov) - Feb 20, 2014
P2, N=230, Active, not recruiting, Sponsor: Merck KGaA
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: Relationship Between Respiratory Functional Tests and Image Thoracic Techniques in Patients With Neuromuscular Diseases (clinicaltrials.gov) - Feb 20, 2014
P=N/A, N=5, Completed, Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial completion: Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis (clinicaltrials.gov) - Feb 19, 2014
P2, N=20, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Completed No longer recruiting --> Completed
- | ifosfamide / Generic mfg., vinorelbine tartrate / Generic mfg.
Trial completion: Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 19, 2014
P2, N=66, Completed, Sponsor: Children's Oncology Group
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Zinbryta (daclizumab) / Biogen, AbbVie
Trial completion: Zenapax to Treat Multiple Sclerosis (clinicaltrials.gov) - Feb 19, 2014
P2, N=22, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Copaxone/Zocor (glatiramer acetate/simvastatin) / Sanofi
Trial withdrawal: Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis (clinicaltrials.gov) - Feb 18, 2014
P3, N=0, Withdrawn, Sponsor: Anna Tsakiri
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Copaxone/Zocor (glatiramer acetate/simvastatin) / Sanofi
Enrollment change: Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis (clinicaltrials.gov) - Feb 18, 2014
P3, N=0, Withdrawn, Sponsor: Anna Tsakiri
Not yet recruiting --> Withdrawn N=20 --> 0
- | Enrollment change: A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis (clinicaltrials.gov) - Feb 17, 2014
P3, N=600, Recruiting, Sponsor: Department of Veterans Affairs
N=20 --> 0 N=200 --> 600
- | H.P. Acthar Gel (repository corticotropin injection) / Mallinckrodt
Enrollment closed: A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis (clinicaltrials.gov) - Feb 17, 2014
P2, N=40, Active, not recruiting, Sponsor: Questcor Pharmaceuticals, Inc.
N=200 --> 600 Recruiting --> Active, not recruiting
- Enrollment change: Hemodynamic Changes in Connective Tissue Disease (clinicaltrials.gov) - Feb 17, 2014
P=N/A, N=85, Completed, Sponsor: Medical University of Graz
Recruiting --> Active, not recruiting N=120 --> 85
- Trial completion: Hemodynamic Changes in Connective Tissue Disease (clinicaltrials.gov) - Feb 17, 2014
P=N/A, N=85, Completed, Sponsor: Medical University of Graz
N=120 --> 85 Recruiting --> Completed
- Trial completion, HEOR: SCLEREDUC: Effects of a Personalized Standardized Rehabilitation Program in Systemic Sclerosis (clinicaltrials.gov) - Feb 16, 2014
P=N/A, N=220, Completed, Sponsor: Assistance Publique - H
Recruiting --> Completed Active, not recruiting --> Completed
- || Rebif (human IFN-β-1a) / EMD Serono
Enrollment change, Adherence: MEASURE: Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects (clinicaltrials.gov) - Feb 15, 2014
P=N/A, N=188, Active, not recruiting, Sponsor: Merck KGaA
Active, not recruiting --> Completed N=306 --> 188
- ||||| Rebif (human IFN-β-1a) / EMD Serono
New P4 trial: RELIEF: A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis (clinicaltrials.gov) - Feb 13, 2014
P4, N=218, Not yet recruiting, Sponsor: Merck KGaA
- | otilimab (GSK3196165) / GSK
Trial completion: Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis (clinicaltrials.gov) - Feb 13, 2014
P1/2, N=30, Completed, Sponsor: MorphoSys AG
N=306 --> 188 Recruiting --> Completed
- Trial termination: CMM-EM: Mesenchymal Stem Cell Transplantation in MS (clinicaltrials.gov) - Feb 11, 2014
P2, N=9, Terminated, Sponsor: Albert Saiz
Recruiting --> Completed Active, not recruiting --> Terminated; Ended the recruitment in June 2012 for low enrollement accrual
- Enrollment change: CMM-EM: Mesenchymal Stem Cell Transplantation in MS (clinicaltrials.gov) - Feb 11, 2014
P2, N=9, Terminated, Sponsor: Albert Saiz
Active, not recruiting --> Terminated; Ended the recruitment in June 2012 for low enrollement accrual N=16 --> 9
- Enrollment change: Impact of Vitamin A Supplementation on Immune System in Multiple Sclerosis Patients (clinicaltrials.gov) - Feb 11, 2014
P4, N=36, Completed, Sponsor: Tehran University of Medical Sciences
N=16 --> 9 N=30 --> 36